CN113727732B - 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高 - Google Patents

用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高 Download PDF

Info

Publication number
CN113727732B
CN113727732B CN202080030927.3A CN202080030927A CN113727732B CN 113727732 B CN113727732 B CN 113727732B CN 202080030927 A CN202080030927 A CN 202080030927A CN 113727732 B CN113727732 B CN 113727732B
Authority
CN
China
Prior art keywords
seq
srebf1
complement
position corresponding
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080030927.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113727732A (zh
Inventor
A·舒尔迪纳
N·戈萨利亚
C·范霍特
龚大为
J·A·佩里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
University of Maryland Baltimore
Original Assignee
Regeneron Pharmaceuticals Inc
University of Maryland Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc, University of Maryland Baltimore filed Critical Regeneron Pharmaceuticals Inc
Priority to CN202310867404.XA priority Critical patent/CN116889627A/zh
Publication of CN113727732A publication Critical patent/CN113727732A/zh
Application granted granted Critical
Publication of CN113727732B publication Critical patent/CN113727732B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080030927.3A 2019-03-20 2020-03-19 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高 Active CN113727732B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310867404.XA CN116889627A (zh) 2019-03-20 2020-03-19 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962820893P 2019-03-20 2019-03-20
US62/820,893 2019-03-20
US201962879138P 2019-07-26 2019-07-26
US62/879,138 2019-07-26
PCT/US2020/023532 WO2020191141A1 (en) 2019-03-20 2020-03-19 Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310867404.XA Division CN116889627A (zh) 2019-03-20 2020-03-19 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高

Publications (2)

Publication Number Publication Date
CN113727732A CN113727732A (zh) 2021-11-30
CN113727732B true CN113727732B (zh) 2023-08-08

Family

ID=70289471

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080030927.3A Active CN113727732B (zh) 2019-03-20 2020-03-19 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
CN202310867404.XA Pending CN116889627A (zh) 2019-03-20 2020-03-19 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310867404.XA Pending CN116889627A (zh) 2019-03-20 2020-03-19 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高

Country Status (6)

Country Link
US (2) US11504390B2 (enExample)
EP (1) EP3942048A1 (enExample)
JP (1) JP7574206B2 (enExample)
CN (2) CN113727732B (enExample)
CA (1) CA3133000A1 (enExample)
WO (1) WO2020191141A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201466A1 (en) 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
CN116583291A (zh) * 2020-12-14 2023-08-11 雷杰纳荣制药公司 用抑制素亚基βE(INHBE)抑制剂治疗代谢病症和心血管疾病的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
EP0633875B1 (en) 1992-04-03 1997-01-02 Gist-Brocades N.V. Selective n-acylation of amino alcohols
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
FR2710337B1 (fr) 1993-09-23 1995-12-08 Gerard Coquerel Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6602710B1 (en) 1998-08-27 2003-08-05 Chugai Seiyaku Kabushiki Kaisha Screening method for SREBP pathway-specific inhibitors
GB9916757D0 (en) 1999-07-17 1999-09-15 Glaxo Group Ltd Method
EP1345895B1 (de) 2000-12-21 2006-12-27 Sanofi-Aventis Deutschland GmbH Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
US20080249040A1 (en) 2001-05-18 2008-10-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of sterol regulatory element binding protein 1 (SREBP1) gene expression using short interfering nucleic acid (siNA)
AU2002320621A1 (en) 2001-07-20 2003-03-03 Incyte Genomics, Inc. Structural and cytoskeleton-associated proteins
WO2003033656A2 (en) * 2001-10-16 2003-04-24 Exelixis, Inc. MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE
US20050014177A1 (en) 2003-05-19 2005-01-20 Koustubh Ranade Human sterol response element binding protein 1 (SREBP1) single nucleotide polymorphisms
CA2658183A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
AU2007297388A1 (en) 2006-09-18 2008-03-27 Alnylam Pharmaceuticals, Inc. RNAi modulation of scap and therapeutic uses thereof
JP2010053122A (ja) * 2008-07-31 2010-03-11 Hayashibara Biochem Lab Inc 脂質合成阻害剤
US9187746B2 (en) 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
EP2515901A2 (en) * 2009-12-22 2012-10-31 The Administrators of the Tulane Educational Fund Compositions and methods for treating obesity and diabetes
WO2015100257A1 (en) 2013-12-23 2015-07-02 The General Hospital Corporation Methods and assays for determining reduced brca1 pathway function in a cancer cell
EP3387129A1 (en) 2015-12-10 2018-10-17 Alnylam Pharmaceuticals, Inc. STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CN105441454B (zh) 2015-12-23 2018-12-11 北京大学人民医院 Scap基因突变体及其应用
WO2017191165A1 (en) 2016-05-03 2017-11-09 Lonza Ltd Modulation of lipid metabolism for protein production
CN111655851A (zh) * 2018-01-18 2020-09-11 哥本哈根罗氏创新中心 靶向srebp1的反义寡核苷酸
EP3746070A4 (en) 2018-01-29 2021-09-01 Capulus Therapeutics, LLC SREBP INHIBITORS WITH A 6-LINKED CENTER RING
US11648260B2 (en) 2018-03-29 2023-05-16 Technion Research And Development Foundation Limitted Vesicles comprising a PTEN inhibitor and uses of same
CN109536610B (zh) * 2018-12-05 2020-10-16 西南大学 Setdb1在调控胆固醇途径中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids,severity,progression and regression of coronary atherosclerosis and response to therapy with fluvastatin";LORRAINE SALEK ET AL;《JOURNAL OF MOLECULAR MEDICINE》;20020911;第80卷(第11期);737-744 *

Also Published As

Publication number Publication date
WO2020191141A1 (en) 2020-09-24
CN116889627A (zh) 2023-10-17
CA3133000A1 (en) 2020-09-24
JP7574206B2 (ja) 2024-10-28
EP3942048A1 (en) 2022-01-26
CN113727732A (zh) 2021-11-30
US20200297752A1 (en) 2020-09-24
US20230263821A1 (en) 2023-08-24
US11504390B2 (en) 2022-11-22
JP2022525545A (ja) 2022-05-17

Similar Documents

Publication Publication Date Title
KR101866152B1 (ko) 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
US11359246B2 (en) Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors
CN113727732B (zh) 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
CA3244298A1 (en) TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL VARIANTS 2 (TREM2) AND ITS USES IN THE TREATMENT OF ALZHEIMER'S DISEASE
CN115667548A (zh) 含有Kelch结构域的7B(KLHDC7B)变体及其用途
US20240076674A1 (en) Treatment Of Decreased Bone Mineral Density With Zinc And Ring Finger 3 (ZNRF3) Inhibitors
KR20240159455A (ko) 신경성 유전자좌 노치 상동체 단백질 3(notch3) 제제를 이용한 뇌혈관 질환의 치료
KR20240043752A (ko) 막횡단 단백질 1(kremen1) 억제제를 함유하는 크링글을 사용하여 감소된 골밀도를 치료하는 방법
CN113825839A (zh) 用固醇调节元件结合蛋白切割激活蛋白(scap)抑制剂治疗脂质水平升高
CN114222588A (zh) 巨噬细胞刺激1受体(mst1r)变体及其用途
EP4395888A1 (en) Treatment of liver diseases with camp responsive element binding protein 3 like 3 (creb3l3) inhibitors
KR20240043753A (ko) Wnt 패밀리 구성원 5B(WNT5B) 저해제를 사용한 감소된 골밀도의 치료
KR20240031334A (ko) 용질 담체 계열 27 구성원 3 (slc27a3) 억제제를 이용한 천식 치료 방법
US20230034093A1 (en) Treatment Of Cognitive Impairment With Alpha-N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 5 (ST6GALNAC5) Inhibitors
CN114846157A (zh) 腺苷酸环化酶7(adcy7)变体及其用途
AU2022303368A1 (en) Treatment of hypertension with solute carrier family 9 isoform a3 regulatory factor 2 (slc9a3r2) inhibitors
CN117651770A (zh) 使用溶质载剂家族9同工型a3调控因子2(slc9a3r2)抑制剂治疗高血压

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant